This study began by exposing human chondrocytes in vitro to the SASP factor IL-1β in order to drive them senescent, then administering ESC-sEVs to a treatment group of cells for a week. The cells successfully began uptaking the ESC-sEVs after 12 hours of exposure. The treatment worked: chrondrocytes exposed to ESC-sEVs had far lower levels of senescence according to the well-known SA-β-gal biomarker, almost to the levels of chrondrocytes not exposed to IL-1β at all. Similarly, markers of extracellular matrix production were restored by the treatment.
1 Like